{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T17:25:24Z","timestamp":1767374724053,"version":"build-2065373602"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.ejmech.2019.111867","type":"journal-article","created":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T19:44:02Z","timestamp":1573587842000},"page":"111867","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Design, synthesis and biological evaluation of new Axl kinase inhibitors containing 1,3,4-oxadiazole acetamide moiety as novel linker"],"prefix":"10.1016","volume":"186","author":[{"given":"Congjun","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yufei","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sicong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruxin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Yue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanfang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2019.111867_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/cancers8110103","article-title":"The receptor tyrosine kinase AXL in cancer progression","volume":"8","author":"Rankin","year":"2016","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2019.111867_bib2","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/ng.2330","article-title":"Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer","volume":"44","author":"Zhang","year":"2012","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejmech.2019.111867_bib3","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.jtho.2016.04.015","article-title":"Axl receptor Axis: a new therapeutic target in lung cancer","volume":"11","author":"Levin","year":"2016","journal-title":"J.\u00a0Thorac. Oncol."},{"key":"10.1016\/j.ejmech.2019.111867_bib4","first-page":"5016","article-title":"axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase","volume":"11","author":"O\u2019Bryan","year":"1991","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.ejmech.2019.111867_bib5","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/0092-8674(95)90520-0","article-title":"The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3\/Axl family of receptor tyrosine kinases","volume":"80","author":"Stitt","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2019.111867_bib6","doi-asserted-by":"crossref","first-page":"8818","DOI":"10.18632\/oncotarget.2422","article-title":"Axl as a mediator of cellular growth and survival","volume":"5","author":"Axelrod","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2019.111867_bib7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.exer.2003.10.002","article-title":"Role of Gas6\/Axl signaling in lens epithelial cell proliferation and survival","volume":"78","author":"P","year":"2004","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.ejmech.2019.111867_bib8","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1084\/jem.20120493","article-title":"Identification of Axl as a downstream effector of TGF-\u03b21 during Langerhans cell differentiation and epidermal homeostasis","volume":"209","author":"Bauer","year":"2012","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ejmech.2019.111867_bib9","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/jcp.20265","article-title":"Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor","volume":"204","author":"Sainaghi","year":"2005","journal-title":"J.\u00a0Cell. Physiol."},{"key":"10.1016\/j.ejmech.2019.111867_bib10","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1158\/0008-5472.CAN-07-2661","article-title":"AXL is a potential target for therapeutic intervention in breast cancer progression","volume":"68","author":"Yi-Xiang","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2019.111867_bib11","doi-asserted-by":"crossref","first-page":"618","DOI":"10.4161\/cbt.8.7.7923","article-title":"The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target","volume":"8","author":"Koorstra","year":"2009","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ejmech.2019.111867_bib12","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1182\/blood-2013-03-491431","article-title":"Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma","volume":"122","author":"Ben-Batalla","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2019.111867_bib13","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1158\/1078-0432.CCR-12-1558","article-title":"An epithelial\u2013mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies axl as a therapeutic target for overcoming EGFR inhibitor resistance","volume":"19","author":"Byers","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2019.111867_bib14","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1158\/0008-5472.CAN-13-1103","article-title":"MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation","volume":"74","author":"Rho","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2019.111867_bib15","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Investigators, M., Cabozantinib versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2019.111867_bib16","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1158\/1078-0432.CCR-10-0574","article-title":"A\u00a0phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2","volume":"16","author":"Eder","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2019.111867_bib17","doi-asserted-by":"crossref","first-page":"6871","DOI":"10.1158\/0008-5472.CAN-08-4490","article-title":"Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL","volume":"69","author":"Liu","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2019.111867_bib18","doi-asserted-by":"crossref","first-page":"8009","DOI":"10.1158\/0008-5472.CAN-08-4889","article-title":"Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases","volume":"69","author":"Qian","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2019.111867_bib19","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1021\/acs.jmedchem.7b01605","article-title":"Development of potent inhibitors of receptor tyrosine kinases by ligand-based drug design and target-biased phenotypic screening","volume":"61","author":"Myers","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111867_bib20","doi-asserted-by":"crossref","first-page":"6807","DOI":"10.1021\/acs.jmedchem.6b00608","article-title":"4-Oxo-1,4-dihydroquinoline-3-carboxamide derivatives as new axl kinase inhibitors","volume":"59","author":"Tan","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111867_bib21","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ejmech.2019.01.065","article-title":"Quinolone antibiotic derivatives as new selective Axl kinase inhibitors","volume":"166","author":"Tan","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111867_bib22","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1021\/acs.jmedchem.5b01273","article-title":"AXL inhibitors in cancer: a medicinal chemistry perspective","volume":"59","author":"Myers","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111867_bib23","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejmech.2013.04.001","article-title":"Design, synthesis and antitumour activity of bisquinoline derivatives connected by 4-oxy-3-fluoroaniline moiety","volume":"64","author":"Li","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111867_bib24","doi-asserted-by":"crossref","first-page":"111707","DOI":"10.1016\/j.ejmech.2019.111707","article-title":"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer\u2019s disease","volume":"183","author":"Tripathi","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111867_bib25","doi-asserted-by":"crossref","first-page":"111693","DOI":"10.1016\/j.ejmech.2019.111693","article-title":"New oxadiazoles with selective-COX-2 and EGFR dual inhibitory activity: design, synthesis, cytotoxicity evaluation and in silico studies","volume":"183","author":"El-Sayed","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111867_bib26","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1021\/acs.jmedchem.8b00457","article-title":"Structure-activity relationships, and preclinical evaluation of heteroaromatic amides and 1,3,4-oxadiazole derivatives as 5-HT4 receptor partial agonists","volume":"61","author":"Nirogi","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111867_bib27","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1124\/dmd.115.063610","article-title":"Metabolism and disposition of Cabozantinib in healthy male volunteers and pharmacologic characterization of its major metabolites","volume":"43","author":"Lacy","year":"2015","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejmech.2019.111867_bib28","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ejmech.2015.04.051","article-title":"1,3,4-Oxadiazoles: an emerging scaffold to target growth factors, enzymes and kinases as anticancer agents","volume":"97","author":"Bajaj","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111867_bib29","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1021\/jm2013248","article-title":"Oxadiazoles in medicinal chemistry","volume":"55","author":"Bostrom","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111867_bib30","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejmech.2016.04.035","article-title":"Discovery of a novel 6,7-disubstituted-4-(2-fluorophenoxy)quinolines bearing 1,2,3-triazole-4-carboxamide moiety as potent c-Met kinase inhibitors","volume":"119","author":"Liu","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111867_bib31","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1021\/ol5033909","article-title":"Intramolecular cycloadditions of photogenerated azaxylylenes with oxadiazoles provide direct access to versatile polyheterocyclic ketopiperazines containing a spiro-oxirane moiety","volume":"17","author":"Kumar","year":"2015","journal-title":"Org. Lett."},{"key":"10.1016\/j.ejmech.2019.111867_bib32","doi-asserted-by":"crossref","first-page":"5999","DOI":"10.1016\/j.tet.2014.05.036","article-title":"Polarization effects in mesogenic isoxazoles and 1,3,4-oxadiazoles","volume":"70","author":"Lu","year":"2014","journal-title":"Tetrahedron"},{"key":"10.1016\/j.ejmech.2019.111867_bib33","doi-asserted-by":"crossref","first-page":"4377","DOI":"10.1021\/jm800639h","article-title":"Oxadiazole-carbonylaminothioureas as SIRT1 and SIRT2 inhibitors","volume":"51","author":"Huhtiniemi","year":"2008","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111867_bib34","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ejmech.2015.06.022","article-title":"Probing the \u2018bipolar\u2019 nature of the carbonic anhydrase active site: aromatic sulfonamides containing 1,3-oxazol-5-yl moiety as picomolar inhibitors of cytosolic CA I and CA II isoforms","volume":"101","author":"Krasavin","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111867_bib35","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1021\/acs.jmedchem.5b01910","article-title":"Discovery of highly potent inhibitors targeting the predominant drug-resistant S31N mutant of the influenza A virus M2 proton channel","volume":"59","author":"Li","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111867_bib36","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cellimm.2018.05.004","article-title":"A\u00a0novel AXL chimeric antigen receptor endows T cells with anti-tumor effects against triple negative breast cancers","volume":"331","author":"Wei","year":"2018","journal-title":"Cell. Immunol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419310190?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419310190?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:07:25Z","timestamp":1759327645000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523419310190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":36,"alternative-id":["S0223523419310190"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.111867","relation":{},"ISSN":["0223-5234"],"issn-type":[{"type":"print","value":"0223-5234"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and biological evaluation of new Axl kinase inhibitors containing 1,3,4-oxadiazole acetamide moiety as novel linker","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.111867","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"111867"}}